not receive SOLESTA. People who have active inflammation of their bowels (Crohn s disease or ulcerative colitis) should not receive SOLESTA. People who have trouble fighting off... (methylnaltrexone bromide) Subcutaneous Injection if you have or may have a blockage in your intestines called a mechanical bowel obstruction. Symptoms of this blockage are vomiting... illness patients with certain conditions (i.e., cancer, peptic ulcer, Ogilvie s syndrome). These holes or openings have involved varying regions of the GI tract (e.g., stomach...

Initiated XIFAXAN Retreatment Trial for Irritable Bowel Syndrome with Diarrhea in February 2012 GIAZO Approved for Treatment of Ulcerative Colitis Submitted sNDA for RELISTOR Subcutaneous... in The New England Journal of Medicine for Irritable Bowel Syndrome without Constipation Acquired Rights to RELISTOR Worldwide (excluding Japan) Acquired Oceana Therapeutics... 2012 adjusted net income forecast is as follows: The current annualized run rates, based on dollarizing the January 2012 prescription data for XIFAXAN, our bowel cleansing products...

#P1571: Lembo et al, Responsiveness of a tri-component endpoint in non-constipation irritable bowel syndrome: pooled results from two phase 3 trials, TARGET 1 and TARGET 2 Poster #P856... Presidents Plenary Session Oral Presentation: Aron et al, Mesalamine granules 1500 mg once daily for 12 weeks provides adequate relief of IBS symptoms in irritable bowel syndrome... markets rifaximin in Italy under the trade name Normix. Indication for APRISO APRISO is a locally acting aminosalicylate indicated for the maintenance of remission of ulcerative...

for 2012 compared to 2011 is due primarily to increased expenses related to our Phase 3 retreatment study of rifaximin for irritable bowel syndrome with diarrhea. Selling, general... the efficacy and safety of repeat treatment with rifaximin 550 mg TID (three times daily) for 14 days in subjects with irritable bowel syndrome with diarrhea (IBS-D) who respond... for any product for treatment of irritable bowel syndrome that might be approved in the future. Under the new arrangements, Salix has provided Alfa Wassermann with rights to obtain...